Cargando…

An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.

PURPOSE: The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids. METHODS: A Delphi method was used. A Board of specialists elaborated and discussed a seri...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattia, Consalvo, Luongo, Livio, Innamorato, Massimo, Melis, Luca, Sofia, Michele, Zappi, Lucia, Puntillo, Filomena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519776/
https://www.ncbi.nlm.nih.gov/pubmed/34675646
http://dx.doi.org/10.2147/JPR.S314206
_version_ 1784584522582458368
author Mattia, Consalvo
Luongo, Livio
Innamorato, Massimo
Melis, Luca
Sofia, Michele
Zappi, Lucia
Puntillo, Filomena
author_facet Mattia, Consalvo
Luongo, Livio
Innamorato, Massimo
Melis, Luca
Sofia, Michele
Zappi, Lucia
Puntillo, Filomena
author_sort Mattia, Consalvo
collection PubMed
description PURPOSE: The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids. METHODS: A Delphi method was used. A Board of specialists elaborated and discussed a series of statements, based on available literature and personal clinical expertise, about particularly controversial topics on pain pathophysiology and treatment. A Panel of experts in the field of pain management, selected by the Board, was invited to vote the proposed statements, indicating the level of agreement on a 5-point Likert scale (1: strongly disagree; 2: disagree; 3: partially agree; 4: agree; 5: strongly agree). The threshold for consensus was set at minimum 66.6% of the number of respondents with a level of agreement ≥4 (Agree or Strongly agree). RESULTS: The Board included 5 pain therapists, 1 pharmacologist and 1 methodology expert and drew up a total of 36 statements (for a total of 40 requested answers)”. A total of 100 clinicians were included in the Expert Panel. Respondents were 89 (89%). Consensus was achieved for 32 out of 40 answers. Most of the lack of consensus was recorded for statements regarding opioids use, and resulted from a low level of agreement (3 on the Likert scale), suggesting a neutral position deriving from a lack of knowledge rather than a strong contrary opinion. CONCLUSION: Most of the proposed items reached consensus, suggesting a generally homogeneous approach to CNCP management. However, the lack of consensus recorded for several items regarding opioid use confirms the need to fill important gaps in the knowledge of available agents. A clear explanation of the peculiar pharmacological properties of drugs associated with potential clinical advantages (such as buprenorphine) will help optimize pain treatment in both primary care and hospital settings and improving pain control in CNCP patients.
format Online
Article
Text
id pubmed-8519776
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-85197762021-10-20 An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine. Mattia, Consalvo Luongo, Livio Innamorato, Massimo Melis, Luca Sofia, Michele Zappi, Lucia Puntillo, Filomena J Pain Res Original Research PURPOSE: The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids. METHODS: A Delphi method was used. A Board of specialists elaborated and discussed a series of statements, based on available literature and personal clinical expertise, about particularly controversial topics on pain pathophysiology and treatment. A Panel of experts in the field of pain management, selected by the Board, was invited to vote the proposed statements, indicating the level of agreement on a 5-point Likert scale (1: strongly disagree; 2: disagree; 3: partially agree; 4: agree; 5: strongly agree). The threshold for consensus was set at minimum 66.6% of the number of respondents with a level of agreement ≥4 (Agree or Strongly agree). RESULTS: The Board included 5 pain therapists, 1 pharmacologist and 1 methodology expert and drew up a total of 36 statements (for a total of 40 requested answers)”. A total of 100 clinicians were included in the Expert Panel. Respondents were 89 (89%). Consensus was achieved for 32 out of 40 answers. Most of the lack of consensus was recorded for statements regarding opioids use, and resulted from a low level of agreement (3 on the Likert scale), suggesting a neutral position deriving from a lack of knowledge rather than a strong contrary opinion. CONCLUSION: Most of the proposed items reached consensus, suggesting a generally homogeneous approach to CNCP management. However, the lack of consensus recorded for several items regarding opioid use confirms the need to fill important gaps in the knowledge of available agents. A clear explanation of the peculiar pharmacological properties of drugs associated with potential clinical advantages (such as buprenorphine) will help optimize pain treatment in both primary care and hospital settings and improving pain control in CNCP patients. Dove 2021-10-11 /pmc/articles/PMC8519776/ /pubmed/34675646 http://dx.doi.org/10.2147/JPR.S314206 Text en © 2021 Mattia et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mattia, Consalvo
Luongo, Livio
Innamorato, Massimo
Melis, Luca
Sofia, Michele
Zappi, Lucia
Puntillo, Filomena
An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.
title An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.
title_full An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.
title_fullStr An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.
title_full_unstemmed An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.
title_short An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine.
title_sort italian expert consensus on the use of opioids for the management of chronic non-oncological pain in clinical practice: focus on buprenorphine.
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519776/
https://www.ncbi.nlm.nih.gov/pubmed/34675646
http://dx.doi.org/10.2147/JPR.S314206
work_keys_str_mv AT mattiaconsalvo anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT luongolivio anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT innamoratomassimo anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT melisluca anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT sofiamichele anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT zappilucia anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT puntillofilomena anitalianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT mattiaconsalvo italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT luongolivio italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT innamoratomassimo italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT melisluca italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT sofiamichele italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT zappilucia italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine
AT puntillofilomena italianexpertconsensusontheuseofopioidsforthemanagementofchronicnononcologicalpaininclinicalpracticefocusonbuprenorphine